Sosei

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

Retrieved on: 
Wednesday, March 27, 2024
Annual, EVP, Patient, Optimism, Change, Sosei, Fine chemical

Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo.
  • In addition, the “Partial Amendment to the Articles of Incorporation (Change of Corporate Name)” was approved at the Annual Shareholder’s Meeting.
  • With this approval, the Company will change its name to Nxera Pharma Co., Ltd. with effect from 1 April 2024.
  • Shinichi Tamura, Chairman of Sosei Heptares, said: “2023 was a transformational year for Sosei Group enabling us to accelerate our development going forward as an integrated, technology powered, commercial-stage biopharmaceutical company focused on applying cutting-edge science to deliver life-changing medicines for patients in Japan and globally.

Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office

Retrieved on: 
Thursday, February 15, 2024
Acquisition, Mergers and acquisitions, Head Office, Sosei, IPJ, Head, Effective date

This is to amend Article 1 (Corporate Name) and Article 3 (Head Office) of the current Articles of Incorporation to make the change of corporate name of the Company mentioned in 1 and the change of the location of the Company mentioned in 2 above.

Key Points: 
  • This is to amend Article 1 (Corporate Name) and Article 3 (Head Office) of the current Articles of Incorporation to make the change of corporate name of the Company mentioned in 1 and the change of the location of the Company mentioned in 2 above.
  • The name of the Company shall be “Sosei Group Kabushiki Kaisha,” and shall be “Sosei Group Corporation” in English.
  • The Head Office of the Company shall be located in Chiyoda-ku, Tokyo, Japan.
  • The name of the Company shall be “Nxera Pharma Kabushiki Kaisha,” and shall be “Nxera Pharma Co., Ltd.” in English.

Sosei Heptares and InveniAI Enter a Multi-Target AI-Powered and GPCR-Focused Drug Discovery Collaboration

Retrieved on: 
Tuesday, July 6, 2021
Sosei, Drug discovery, Health

The collaboration will combine InveniAI's AI-powered platform, AlphaMeld, for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities to generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.

Key Points: 
  • The collaboration will combine InveniAI's AI-powered platform, AlphaMeld, for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities to generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.
  • This collaboration has the potential to further extend our GPCR-focused drug discovery and early development capabilities.
  • This collaboration will leverage InveniAIs AI-based high-throughput discovery pipeline with Sosei Heptares complementary chemistry approach to deliver drug candidates efficiently, at scale, and with an enhanced probability of clinical success.
  • Sosei Heptares is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

Retrieved on: 
Tuesday, July 6, 2021
Sosei, Drug discovery, Health

The collaboration will combine InveniAI's AI-powered platform for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.

Key Points: 
  • The collaboration will combine InveniAI's AI-powered platform for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.
  • This collaboration has the potential to further extend our GPCR-focused drug discovery and early development capabilities.
  • This collaboration will leverage InveniAI's AI-based high-throughput discovery pipeline with Sosei Heptares' complementary chemistry approach to deliver drug candidates efficiently, at a scale, and with an enhanced probability of clinical success.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

Retrieved on: 
Tuesday, July 6, 2021
Sosei, Drug discovery, Health

The collaboration will combine InveniAI's AI-powered platform for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.

Key Points: 
  • The collaboration will combine InveniAI's AI-powered platform for target discovery with Sosei Heptares' world-leading GPCR structure-based drug design and early development capabilities generate and advance transformative therapeutics across disease indications that remain with high unmet medical needs.
  • This collaboration has the potential to further extend our GPCR-focused drug discovery and early development capabilities.
  • This collaboration will leverage InveniAI's AI-based high-throughput discovery pipeline with Sosei Heptares' complementary chemistry approach to deliver drug candidates efficiently, at a scale, and with an enhanced probability of clinical success.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Retrieved on: 
Wednesday, June 23, 2021
Calcitonin gene-related peptide, Neuropeptides, CALCRL, Sosei

Sosei Heptares has advanced HTL0022562 successfully though a preclinical development program demonstrating its promising and differentiated properties for further investigation in human trials.

Key Points: 
  • Sosei Heptares has advanced HTL0022562 successfully though a preclinical development program demonstrating its promising and differentiated properties for further investigation in human trials.
  • Under the global collaboration and license agreement with Biohaven, Sosei Heptares will conduct the Phase 1 clinical trial itself, receiving a milestone payment for its initiation, and is also eligible for development costs for conducting the trial.
  • Biohaven will lead all future studies and development activities and Sosei Heptares will be eligible for further milestone payments and royalties.
  • Sosei Heptares and Biohaven entered a global collaboration and license agreement in December 2020 under which Biohaven received exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders.

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Retrieved on: 
Thursday, March 11, 2021
Sosei

The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.

Key Points: 
  • The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.
  • Under the terms of the sale to Formosa in 2017, Sosei Heptares is entitled to receive undisclosed milestone payments based on progression of Activus' pipeline as well as royalties from the commercialization of certain products should they reach the market.
  • Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, said:"It is great to see the progress that Formosa has made advancing the development of APP13007.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals

Retrieved on: 
Thursday, March 11, 2021
Sosei

The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.

Key Points: 
  • The milestone has triggered a US$2.5 million payment to Sosei Heptares from Formosa.
  • Under the terms of the sale to Formosa in 2017, Sosei Heptares is entitled to receive undisclosed milestone payments based on progression of Activus' pipeline as well as royalties from the commercialization of certain products should they reach the market.
  • Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, said:"It is great to see the progress that Formosa has made advancing the development of APP13007.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares spin-off company Orexia Therapeutics merged into newly created Centessa Pharmaceuticals

Retrieved on: 
Tuesday, February 16, 2021
Sosei

Orexia Therapeutics ("Orexia"), a new entity comprising Orexia Limited and Inexia Limited, which were created in February 2019 by Sosei Heptares and Medicxi, has been merged into Centessa.

Key Points: 
  • Orexia Therapeutics ("Orexia"), a new entity comprising Orexia Limited and Inexia Limited, which were created in February 2019 by Sosei Heptares and Medicxi, has been merged into Centessa.
  • Sosei Heptares continues to provide research services to Orexia and its equity holding in Orexia has been converted into a proportional shareholding in Centessa.
  • Miles Congreve, Chief Scientific Officer of Sosei Heptares, commented:"This is a very exciting development for Orexia and we are delighted that it has been selected to be part of Centessa.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).

Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020

Retrieved on: 
Friday, February 12, 2021
Sosei, Tokyo Stock Exchange, Economy of Japan

TOKYO and CAMBRIDGE, England, Feb. 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020.

Key Points: 
  • TOKYO and CAMBRIDGE, England, Feb. 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020.
  • Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented:"Sosei Heptares made a great deal of progress across all areas of its business in 2020, despite the challenges we faced.
  • "Sosei Heptares" is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).
  • Sosei, Heptares, the logo and StaR are trademarks of Sosei Group companies.